Different angiotensin-converting enzyme inhibitors have similar clinical efficacy after myocardial infarction.
BACKGROUND
Treatment with an angiotensin-converting enzyme (ACE) inhibitor benefits many patients with cardiovascular disease. ACE inhibitors are generally assumed to be equally effective, but this has never been fully verified in clinical trials.


CONCLUSIONS
Studying the association among ACE inhibitors after myocardial infarction demonstrated similarity in clinical outcome and supports a dosage-response relationship. Therefore, for long-term benefits for patients who need treatment with an ACE inhibitor, a focus of treatment at the recommended dosage is most important and not which ACE inhibitor is used.


OBJECTIVE
Therapy with angiotensin-converting enzyme (ACE) inhibitors is common after myocardial infarction (MI). Given the lack of randomized trials comparing different ACE inhibitors, the association among ACE inhibitors after MI in risk for mortality and reinfarction was studied.


METHODS
Patients hospitalized with first-time MI (n = 16,068) between 1995 and 2002, who survived at least 30 days after discharge and claimed at least one prescription of ACE inhibitor, were identified using nationwide administrative registries in Denmark.


RESULTS
Adjusted Cox regression analysis demonstrated no differences in risk for all-cause mortality, but patients using captopril had higher risk of reinfarction (hazard ratio 1.18, 95% confidence interval 1.05, 1.34). However, following adjustment for differences in used dosages, all ACE inhibitors had similar clinical efficacy. Risk of all-cause mortality: trandolapril (reference) 1.00, ramipril 0.97 (0.89, 1.05), enalapril 1.04 (0.95, 1.150), captopril 0.95 (0.83, 1.08), perindopril 0.98 (0.84, 1.15) and other ACE inhibitors or angiotensin II receptor blockers (ARB) 1.06 (0.94, 1.19). Reinfarction: trandolapril (reference) 1.00, ramipril 0.98 (0.89, 1.08), enalapril 1.04 (0.92, 1.17), captopril 1.05 (0.89, 1.25), perindopril 0.96 (0.81, 1.14) and other ACE inhibitors or ARB 0.99 (0.86, 1.14). Furthermore, the association between ARBs and clinical events was similar to ACE inhibitors (trandolapril reference): all-cause mortality 0.99 (0.84, 1.16) and recurrent MI 0.99 (0.83, 1.19).


CONCLUSIONS
Our results suggest a class effect among ACE inhibitors when used in comparable dosages. Focus on treatment at the recommended dosage is therefore most important, and not which ACE inhibitor is used.
Hansen
Morten L
ML
Department of Cardiovascular Medicine, Bispebjerg University Hospital, Copenhagen, Denmark. mlh@heart.dk
Gislason
Gunnar H
GH
Køber
Lars
L
Schramm
Tina Ken
TK
Folke
Fredrik
F
Buch
Pernille
P
Abildstrom
Steen Z
SZ
Madsen
Mette
M
Rasmussen
Søren
S
Torp-Pedersen
Christian
C
D000368:Aged; D000369:Aged, 80 and over; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D015331:Cohort Studies; D005260:Female; D017052:Hospital Mortality / Q000639:trends; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000201:enzymology* / Q000401:mortality; D012042:Registries
D000806:Angiotensin-Converting Enzyme Inhibitors
N Engl J Med. 1992 Sep 3;327(10):669-77
1386652
Eur Heart J. 2006 May;27(10):1153-8
16399775
Lancet. 1993 Oct 2;342(8875):821-8
8104270
Lancet. 1994 May 7;343(8906):1115-22
7910229
Am J Cardiol. 1994 Jun 15;73(16):1180-6
8203335
Lancet. 1995 Mar 18;345(8951):669-85
7661937
Lancet. 1995 Mar 18;345(8951):686-7
7885123
N Engl J Med. 1995 Dec 21;333(25):1670-6
7477219
J Clin Epidemiol. 1997 Jan;50(1):105-16
9048695
Br J Clin Pharmacol. 1997 Apr;43(4):429-33
9146856
Dan Med Bull. 1997 Sep;44(4):445-8
9377907
Circulation. 1999 Dec 7;100(23):2312-8
10587334
N Engl J Med. 2000 Jan 20;342(3):145-53
10639539
Lancet. 2000 May 6;355(9215):1575-81
10821360
Lancet. 2000 May 6;355(9215):1582-7
10821361
Arch Intern Med. 2001 Jan 22;161(2):183-8
11176731
Lancet. 2002 Sep 7;360(9335):752-60
12241832
Pharmacoeconomics. 2003;21(2):89-103
12515571
Eur Heart J. 2003 Jan;24(1):28-66
12559937
J Clin Epidemiol. 2003 Feb;56(2):124-30
12654406
Lancet. 2003 Sep 6;362(9386):782-8
13678872
N Engl J Med. 2003 Nov 13;349(20):1893-906
14610160
Ann Intern Med. 2004 Jul 20;141(2):102-12
15262665
Eur Heart J. 2004 Aug;25(16):1454-70
15302105
N Engl J Med. 1991 Aug 1;325(5):293-302
2057034
N Engl J Med. 1991 Aug 1;325(5):303-10
2057035
N Engl J Med. 2004 Nov 11;351(20):2058-68
15531767
Am J Cardiol. 2005 Jan 15;95(2):283-6
15642572
Eur Heart J. 2005 May;26(10):990-5
15618048
Scand Cardiovasc J. 2005 Apr;39(1-2):42-9
16097413
Med Care. 2005 Oct;43(10):970-8
16166866
Eur Heart J. 2006 Apr;27(7):796-801
16497685
Lancet. 1993 Mar 27;341(8848):829
8096029